SPEAKER:
Bill Coyle, Managing Principal – Europe, ZS
KEY TAKEAWAYS:
• MFN pricing policy converts European launch decisions into direct threats against US revenue
• German survey data shows 40% of patients avoid care entirely, breaking the commercial funnel upstream
• Chinese biopharma runs trials 40% shorter and 35% cheaper, with no US reference price to protect
• AI-enabled tools compress commercial planning to 30–40% of prior timelines, shifting launch viability thresholds
• Companies delaying European launches may be vacating the market for competitors structurally incapable of retreating
"The rules of the game today aren't going to be the rules of the game in the coming years that we need to navigate to successfully bring our products to patients." Bill Coyle said that at Pharma 2026, and the framing understates the problem. The rules aren't shifting gradually. They are being rewritten by three concurrent pressures that interact in a way none of them would produce alone.
The mechanism connecting them is MFN. "MFN is creating a huge hesitation to launch here in Europe if it exposes price in the US, which of course is the major driver of profit for the entire industry," Coyle argued. That hesitation is individually rational. Modelled at the asset level, delaying a European launch to protect a US reference price can be the correct decision. Modelled at the portfolio level, across a market, it produces a different outcome — one that European commercial leadership teams should be far more uncomfortable with than current strategy discussions suggest.
The Vacuum Western Pharma Is Creating
Work through the decision tree a US-headquartered company faces under MFN. A European launch at a price that satisfies HTA bodies in Germany, France, or Italy risks becoming the floor for US negotiations. The rational responses — delay, restrict launch sequence, price above HTA acceptance thresholds — are all individually defensible. Collectively, they thin the European innovative medicine pipeline and create extended windows of uncontested market opportunity.
Chinese biopharma is structurally positioned to fill that window. "China has 30% of the global share of innovation," Coyle noted. "A huge amount of our phase one trials, their clinical trials in the early stages are 40% shorter and 35% lower cost." Those are not incremental efficiency advantages. They represent a fundamentally different cost basis for clinical development, one that makes European launch economics viable at price points where Western companies cannot break even.
There is a regulatory dimension Coyle raised whose competitive implications extend further than his session framing suggested. EMA has adopted a pragmatic posture toward bridging studies built on Chinese clinical data, reflecting both the quality improvements in Chinese trial execution and the agency's access mandate. FDA has been considerably more resistant. That asymmetry specifically advantages Chinese assets in European markets, and it means the competitive threat is not contingent on Chinese companies achieving FDA approval first. Europe is the accessible market.
The domestic economics make this expansion structurally inevitable rather than opportunistic. China's National Reimbursement Drug List negotiation process, as Coyle described it, "brings prices down closer to zero than to a palatable European price." A Chinese innovator that achieves NRDL listing has essentially confirmed that domestic revenues alone cannot sustain the asset's commercial viability. Western revenues are not a growth opportunity for them; they are an economic requirement.
The logical chain closes quickly. "If we're not able to develop and bring innovative assets to the US and Europe simultaneously due to MFN, does this create an opportunity for Chinese manufacturers to really focus on Europe as their home marketplace?" Coyle asked. The answer embedded in the economics is yes. And the answer to why they would pursue it is equally clear: "For the domestic China pharma ecosystem to thrive, they need to come west."
Companies currently modelling European launch strategy as a pricing decision are misspecifying the problem. It is a competitive positioning decision with a time horizon. The relevant question is not whether a European price harms US negotiations — it is how long the resulting gap in market presence remains before a competitor with no US price to protect occupies it.
The Patient Funnel That Doesn't Exist
"68% only seek care when they're sick and almost 40% avoid seeking care because it's a hassle, because it's difficult to get an appointment. 31% don't trust the system." That data, drawn from a 1,500-person German consumer survey, is worth pausing on — not as a patient satisfaction finding but as a commercial infrastructure problem.
Every European launch model assumes patients enter healthcare systems. Physician targeting, payer engagement, and formulary access optimisation all operate downstream of that assumption. What the German data indicates is that for any therapy addressing underdiagnosed or undertreated conditions, the addressable patient population in standard commercial models is substantially overstated. The funnel has a structural leak upstream of the first prescribing moment, and pharma's promotional machinery operates entirely below it.
The operational response Coyle described in renal disease is the most concrete proof point available. A pharma company working with German nephrologists co-developed a digital self-assessment tool targeting symptom patterns that precede diagnosis. "The KOLs like the self assessment that they helped create," Coyle explained. "So much so they've opened up direct booking through Doctolib directly into their COEs in Germany. So if a patient goes through the self assessment, they bypass GPs and they can go directly to the COEs where they'll open up appointments to get them to come in and be properly diagnosed."
The replicable architecture is: symptom-targeted awareness, validated digital self-assessment, clinician-endorsed output, direct specialist access. What makes it work is clinician co-creation. The tool carries credibility because the KOLs built it, and they protect its integrity because their diagnosis pipeline depends on it. Pharma is not running a patient recruitment programme; it is building shared infrastructure that the clinical community has a stake in maintaining.
Coyle positioned this as a broader industry obligation, arguing that pharma should step up and solve these systemic access issues in partnership with stakeholders. That framing is accurate, and it is also commercially strategic. Companies that build upstream patient identification pathways establish a structural advantage that precedes any promotional activity. A Chinese competitor entering the European renal market faces not just clinical competition but an established patient activation pathway built around a different company's diagnostic tool and specialist relationships. That moat is not visible in pipeline analyses or HTA submissions. It accrues in the years before launch.
The limits of the model are worth naming. The renal case works because the diagnostic bottleneck is identifiable, specialist centres are concentrated, and the clinical community has a strong interest in earlier diagnosis. In therapeutic areas where primary care remains the dominant access point — cardiovascular prevention, metabolic disease, respiratory management — the bypass-to-specialist architecture does not translate directly. The principle scales; the mechanism requires re-engineering for each therapeutic context.
Discover more on this topic at Pharma Commercial Data & Tech Europe 2026 (4-5 November, London) Europe's collaborative home for data and tech pioneers. Visit the website here.
Compressing the Business Case for European Launches
Even for companies that resolve the MFN calculus and invest in patient pathway infrastructure, European launch economics remain marginal under traditional operating models. HTA-driven price compression, fragmented market access timelines across member states, and promotional cost structures built for higher-margin US commercial environments all contribute to business cases that are borderline at best.
Coyle described a set of AI-enabled tools that are beginning to shift those thresholds. The first concerns the physician influence model. "Increasingly we need to be thinking about influencing the machine, making sure our evidence is in the right places, in addition to influencing physicians to make the right decisions for their patients." Clinical decision support tools, AI-assisted diagnostics, and healthcare-focused LLMs constitute a parallel influence layer that operates independently of the traditional rep-to-physician channel. Positioning evidence within these systems requires deliberate effort upstream of product approval, but it also scales in ways that field force deployment does not.
On commercial planning, Coyle indicated that AI tools are enabling "aspects of using algorithms to do things like marketing mix in 30 to 40% of the time that they used to take to have more dynamic planning versus quarterly or even annual cycles." That compression changes the commercial decision cadence in ways that matter for constrained European budgets. Promotional resources can be reallocated against emerging market signals rather than locked into annual plans built on assumptions that are stale within months of execution.
The research timeline is compressing similarly. "Creating digital twins and personas of market research respondents so we can very rapidly seek insights, test content, check that it's going to be good versus a lengthy expensive market research project," Coyle described. Synthetic respondent modelling is not a replacement for primary research at high-stakes decision points, but it can eliminate the four-to-six-month market research cycles that currently delay launch preparation. For European markets where the commercial window is already narrowed by HTA timelines, that compression is a viability shift, not merely an efficiency gain.
Three Questions That Are Actually One
Coyle presented three distinct challenges: MFN's distortion of European launch economics, the patient access infrastructure problem, and the operational transformation required to make European business cases viable. The strategic danger is treating them as parallel.
They are sequential and self-reinforcing. MFN determines which products enter Europe. Patient pathway dysfunction determines which of those products actually reach patients. Commercial cost compression determines which business cases survive the margin constraints that remain after HTA negotiation. Failure at any stage cascades downstream, and the beneficiary of all three failures is the same set of competitors.
The diagnostic framework for European commercial leadership is more specific than "address all three." The stress-test has three questions. Which assets in the current portfolio become launch-negative if a European price is referenced in US MFN calculations, and what is the combined revenue exposure of delaying those launches by two years? For priority therapeutic areas, what percentage of the eligible patient population never enters the healthcare system in a timely way, and what would it cost to build the upstream pathway before a competitor does? Is there a Chinese innovator developing an asset in the same indication that has no US price to protect, and how far behind are they?
If the answer to the third question is less than three years, the first two questions stop being strategic planning items and become urgent operational priorities.
The window for building European competitive infrastructure is not defined by MFN policy timelines or the pace of HTA reform. It is defined by how quickly Chinese biopharma can complete bridging studies and file with EMA. That clock is already running, and it runs faster than most Western portfolio reviews assume.
To get you highlights of Pharma 2026 faster, we are using generative AI technology to summarise the transcripts of the sessions. If you have any feedback about the summary, please contact lucy.fisher@thomsonreuters.com.
Discover more on this topic at Pharma Commercial Data & Tech Europe 2026 (4-5 November, London) Europe's collaborative home for data and tech pioneers. Visit the website here.
